More than 13,000 physicians in 24 specialty groups recognized Merck as having the best overall reputation among pharmaceutical companies, according to a new report from IMS America, Somerset, NJ, and the Plymouth Group, Plymouth Meeting, PA.
More than 13,000 physicians in 24 specialty groups recognized Merck as having the best overall reputation among pharmaceutical companies, according to a new report from IMS America, Somerset, NJ, and the Plymouth Group, Plymouth Meeting, PA.
Merck was also named best overall company by doctors in nine individual specialties, including general and family practitioners, internists, general surgeons, infectious disease specialists, cardiologists, nephrologists, orthopedic surgeons, rheumatologists and urologists.
The recent launches of three major products - Cozaar, Fosamax and Proscar - were influential in securing Merck its win. The growing popularity of its drugs Zocor and Vasotec may have factored in the report's results as well.
Companies were judged according to four attributes: research and development efforts, product line, educational programs and value-added services.
Physicians also evaluated the performances of pharmaceutical sales forces by their knowledge, professional style, service and sample availability.
The combined response from the 24: Astra-Merck's sales force took top honors among all physicians in every one of the four evaluation categories. It was also named by physicians as one of the two most familiar sales forces. PR
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.